Ali A Asadi-Pooya1,2, Mehdi Bazrafshan1. 1. Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA.
Abstract
PURPOSE: We investigated the rate of employment in patients with functional seizures (FS) in a follow-up study. We also investigated the rate of receiving disability benefits in these patients. Finally, we investigated factors that are potentially associated with their employment status. METHODS: In this long-term study, all patients with FS, who were diagnosed at Shiraz Comprehensive Epilepsy Center, Iran, from 2008 to 2018, were investigated. In a phone call interview to the patients in February 2020, we tried to obtain the following information: seizure outcome, employment status, receiving disability benefits, and their current drug regimen, if any. The first call was made in the evening and after working hours. In case of no response, we made two more attempts in the following weeks to contact the patients during different time periods of the day. RESULTS: Eighty- four patients participated. Thirty-one patients (37%) were employed, and 53 people (63%) were not; at the first visit, the rate of employment was 23%. Female sex (Odds Ratio [OR]: 12.18; 95% Confidence Interval [CI]: 3.51-42.18; p = .0001), taking psychiatric drugs (OR: 4.93; 95% CI: 1.17-20.73; p = .02), and being employed previously (OR: 0.19; 95% CI: 0.04-0.77; p = .02) were independently significantly associated with the current employment status. Three patients (4%) reported receiving disability social benefits, two women and one man. CONCLUSION: This study highlights that unemployment is a serious issue in patients with FS and psychiatric comorbidities play a significant role in the employment status in these patients.
PURPOSE: We investigated the rate of employment in patients with functional seizures (FS) in a follow-up study. We also investigated the rate of receiving disability benefits in these patients. Finally, we investigated factors that are potentially associated with their employment status. METHODS: In this long-term study, all patients with FS, who were diagnosed at Shiraz Comprehensive Epilepsy Center, Iran, from 2008 to 2018, were investigated. In a phone call interview to the patients in February 2020, we tried to obtain the following information: seizure outcome, employment status, receiving disability benefits, and their current drug regimen, if any. The first call was made in the evening and after working hours. In case of no response, we made two more attempts in the following weeks to contact the patients during different time periods of the day. RESULTS: Eighty- four patients participated. Thirty-one patients (37%) were employed, and 53 people (63%) were not; at the first visit, the rate of employment was 23%. Female sex (Odds Ratio [OR]: 12.18; 95% Confidence Interval [CI]: 3.51-42.18; p = .0001), taking psychiatric drugs (OR: 4.93; 95% CI: 1.17-20.73; p = .02), and being employed previously (OR: 0.19; 95% CI: 0.04-0.77; p = .02) were independently significantly associated with the current employment status. Three patients (4%) reported receiving disability social benefits, two women and one man. CONCLUSION: This study highlights that unemployment is a serious issue in patients with FS and psychiatric comorbidities play a significant role in the employment status in these patients.
Authors: Coraline Hingray; Wissam El-Hage; Rod Duncan; David Gigineishvili; Kousuke Kanemoto; W Curt LaFrance; Alejandro de Marinis; Ravi Paul; Chrisma Pretorius; José F Téllez-Zenteno; Hannah Wiseman; Markus Reuber Journal: Epilepsia Date: 2017-11-20 Impact factor: 5.864
Authors: S Gasparini; E Beghi; E Ferlazzo; M Beghi; V Belcastro; K P Biermann; G Bottini; G Capovilla; R A Cervellione; V Cianci; G Coppola; C M Cornaggia; P De Fazio; S De Masi; G De Sarro; M Elia; G Erba; L Fusco; A Gambardella; V Gentile; A T Giallonardo; R Guerrini; F Ingravallo; A Iudice; A Labate; E Lucenteforte; A Magaudda; L Mumoli; C Papagno; G B Pesce; E Pucci; P Ricci; A Romeo; R Quintas; C Sueri; G Vitaliti; R Zoia; U Aguglia Journal: Eur J Neurol Date: 2018-11-29 Impact factor: 6.089